Disulfiram blocks inflammatory TLR4 signaling by targeting MD-2

Area of Science:

• Immunology
• Neuroscience
• Pharmacology

Background:

• Toll-like receptor 4 (TLR4) activation by lipopolysaccharide (LPS) triggers potent inflammatory responses crucial for host defense but implicated in pathologies like sepsis.
• Existing TLR4 inhibitors have failed to demonstrate clinical efficacy, necessitating novel therapeutic strategies.
• Neuroinflammation, driven by TLR4 signaling, contributes to dopaminergic neuron loss in Parkinson's disease (PD).

Purpose of the Study:

• To identify novel inhibitors of TLR4-mediated inflammatory signaling.
• To investigate the therapeutic potential of disulfiram (DSF) in preclinical models of inflammation and neurodegeneration.

Main Methods:

• Disulfiram (DSF) was evaluated for its ability to inhibit TLR4-MD-2 complex formation and signaling.
• DSF's effect on inflammatory mediator production in macrophages was assessed in vitro.
• The N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model was used to study DSF's impact on neuroinflammation and dopaminergic neuron survival.

Main Results:

• Disulfiram (DSF) specifically inhibits TLR4 signaling by covalently modifying Cys133 of the MD-2 protein.
• DSF effectively blocks LPS-induced production of inflammatory cytokines, chemokines, and interferons in macrophages.
• In the MPTP mouse model of Parkinson's disease, DSF significantly reduced neuroinflammation, protected dopaminergic neurons, and improved motor function.

Conclusions:

• Disulfiram (DSF) is a potent inhibitor of TLR4-MD-2 inflammatory signaling.
• DSF demonstrates therapeutic potential for neuroinflammation and neuroprotection in Parkinson's disease models.
• Targeting MD-2 with drugs like DSF may offer a viable strategy for treating inflammatory diseases, including PD.